Clinical Trials · NCT03015220
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 458
- Start date
- Jan 2017
- Locations
- 34 sites, Japan
- Primary endpoint
- Number of Treatment-emergent Adverse Events (TEAEs)